01:38 PM EDT, 09/10/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that efsitora lowered blood sugar in certain adults with type 1 and 2 diabetes in separate phase 3 trials.

The QWINT-2 study compared once-weekly insulin efsitora alfa to once-daily insulin degludec in adults with type 2 diabetes who are new to insulin. Data show efsitora reduced A1C levels by 1.34%, slightly more than the 1.26% reduction seen with insulin degludec, leading to A1C levels of 6.87% and 6.95%, respectively, after 52 weeks, the company said.

Efsitora met the primary endpoint of noninferior A1C reduction. Results were published in The New England Journal of Medicine, the company said.

The QWINT-5 study compared once-weekly insulin efsitora alfa to once-daily insulin degludec in adults with type 1 diabetes who need daily basal and multiple mealtime insulin injections, the company said.

Data show efsitora was as effective as insulin degludec in lowering A1C levels after 26 weeks. The results were published in The Lancet. Findings from both studies were presented at the European Association for the Study of Diabetes annual meeting, the company said.

Eli Lilly ( LLY ) shares fell 0.6% in recent Tuesday trading.

Price: 902.87, Change: -5.40, Percent Change: -0.60